MedTrace Logo

LONG-DES VI (Drug Eluting Stent for Long Lesions in Coronary Artery)

NCT01489761 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 302

Last updated 2017-02-24

No results posted yet for this study

Summary

This is a multi-center, randomized, study to compare the efficacy of zotarolimus-eluting stent (Resolute Integrity or Resolute Onyx stent) or everolimus-eluting stent (Xience Prime or Xience Xpedition or Xience Alpine stent) for very long coronary lesions.

Conditions

Interventions

DEVICE

percutaneous coronary intervention

drug eluting stent implantation

Sponsors & Collaborators

  • Abbott

    collaborator INDUSTRY

  • CardioVascular Research Foundation, Korea

    collaborator OTHER

  • Seung-Jung Park

    lead OTHER

Principal Investigators

  • Seung-Jung Park, MD, PhD · Asan Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2017-02-14
Completion
2017-02-14

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01489761 on ClinicalTrials.gov